Literature DB >> 15683819

Diabetes mellitus and breast cancer.

Ido Wolf1, Siegal Sadetzki, Raphael Catane, Avraham Karasik, Bella Kaufman.   

Abstract

Type 2 diabetes is a serious health problem that affects more than 7% of adults in developed countries. Up to 16% of patients with breast cancer have diabetes, and two major risk factors for type 2 diabetes-old age and obesity-are also associated with breast cancer. Three mechanisms have been postulated to associate diabetes with breast cancer: activation of the insulin pathway, activation of the insulin-like-growth-factor pathway, and regulation of endogenous sex hormones. Comparative cohort studies and case-control studies suggest that type 2 diabetes may be associated with 10-20% excess relative risk of breast cancer. Gestational diabetes mellitus, but not type 1 diabetes, might also be associated with excess risk of breast cancer. Moreover, diabetes and its complications can adversely affect cancer therapy and the use of screening, which will thus affect the outcome of patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683819     DOI: 10.1016/S1470-2045(05)01736-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  120 in total

1.  Pre-Existing Diabetes in Early Stage Breast Cancer Patients is Associated with Lack of Improvement in Quality of Life 2 Years After Diagnosis.

Authors:  Soghra Jarvandi; Maria Pérez; Mario Schootman; Donna B Jeffe
Journal:  Int J Behav Med       Date:  2016-12

Review 2.  Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Authors:  Pushpendra Singh; Jimi Marin Alex; Felix Bast
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

3.  Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.

Authors:  Rui-Jue Wang; Lin-Jie Lu; Liang-Bin Jin; Hong-Yuan Li; Guo-Sheng Ren; Kai-Nan Wu; Sheng-Chun Liu; Ling-Quan Kong
Journal:  Med Oncol       Date:  2013-12-12       Impact factor: 3.064

4.  Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.

Authors:  Sejeong Shin; Laura Wolgamott; Yonghao Yu; John Blenis; Sang-Oh Yoon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 5.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.

Authors:  Gregory S Calip; Onchee Yu; Joann G Elmore; Denise M Boudreau
Journal:  Cancer Causes Control       Date:  2016-04-06       Impact factor: 2.506

7.  Diabetes, diabetes treatment and breast cancer prognosis.

Authors:  Juhua Luo; Beth Virnig; Michael Hendryx; Sijin Wen; Rowan Chelebowski; Chu Chen; Tomas Rohan; Lesley Tinker; Jean Wactawski-Wende; Lawrence Lessin; Karen Margolis
Journal:  Breast Cancer Res Treat       Date:  2014-09-27       Impact factor: 4.872

Review 8.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

9.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

10.  Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study.

Authors:  Elias Immanuel Ordell Sundelin; Nidal Al-Suliman; Pernille Vahl; Mikkel Vendelbo; Ole Lajord Munk; Steen Jakobsen; Steen Bønløkke Pedersen; Jørgen Frøkiær; Lars C Gormsen; Niels Jessen
Journal:  Breast Cancer Res Treat       Date:  2020-04-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.